David A. Sandham

835 total citations
29 papers, 453 citations indexed

About

David A. Sandham is a scholar working on Organic Chemistry, Physiology and Molecular Biology. According to data from OpenAlex, David A. Sandham has authored 29 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Organic Chemistry, 10 papers in Physiology and 9 papers in Molecular Biology. Recurrent topics in David A. Sandham's work include Asthma and respiratory diseases (8 papers), Eosinophilic Esophagitis (5 papers) and Receptor Mechanisms and Signaling (5 papers). David A. Sandham is often cited by papers focused on Asthma and respiratory diseases (8 papers), Eosinophilic Esophagitis (5 papers) and Receptor Mechanisms and Signaling (5 papers). David A. Sandham collaborates with scholars based in United Kingdom, Switzerland and United States. David A. Sandham's co-authors include William B. Motherwell, Veit J. Erpenbeck, Pablo Altman, Óscar Palomares, Stephen Caddick, Christian Domingo, Lewis Gazzard, A. I. MEYERS, John Carey and Roger Taylor and has published in prestigious journals such as The Journal of Immunology, American Journal of Respiratory and Critical Care Medicine and Journal of Medicinal Chemistry.

In The Last Decade

David A. Sandham

27 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David A. Sandham United Kingdom 14 198 132 114 65 50 29 453
Tai Wei Ly Taiwan 13 178 0.9× 139 1.1× 83 0.7× 52 0.8× 42 0.8× 26 435
Arthur G. Romero United States 15 255 1.3× 238 1.8× 94 0.8× 75 1.2× 64 1.3× 21 638
Koichi Nishi Japan 11 115 0.6× 125 0.9× 67 0.6× 99 1.5× 23 0.5× 42 380
Lin Chu United States 8 111 0.6× 148 1.1× 61 0.5× 13 0.2× 30 0.6× 13 364
Fujio Asanuma Japan 12 121 0.6× 123 0.9× 210 1.8× 64 1.0× 59 1.2× 20 472
Herman J. Crowley United States 13 145 0.7× 157 1.2× 82 0.7× 44 0.7× 25 0.5× 24 369
Frederick Wong United States 11 179 0.9× 212 1.6× 47 0.4× 11 0.2× 84 1.7× 18 456
Kazuaki Naito United States 11 49 0.2× 168 1.3× 102 0.9× 41 0.6× 52 1.0× 32 347
Naoyuki Masuda Japan 14 179 0.9× 162 1.2× 31 0.3× 27 0.4× 27 0.5× 27 490
Earl F. Kimble Switzerland 10 105 0.5× 79 0.6× 51 0.4× 18 0.3× 58 1.2× 19 411

Countries citing papers authored by David A. Sandham

Since Specialization
Citations

This map shows the geographic impact of David A. Sandham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Sandham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Sandham more than expected).

Fields of papers citing papers by David A. Sandham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Sandham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Sandham. The network helps show where David A. Sandham may publish in the future.

Co-authorship network of co-authors of David A. Sandham

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Sandham. A scholar is included among the top collaborators of David A. Sandham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Sandham. David A. Sandham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brightling, Christopher E., Swarupa G. Kulkarni, Bart N. Lambrecht, et al.. (2021). The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulmonary Pharmacology & Therapeutics. 68. 102030–102030. 6 indexed citations
2.
Chen, Wentao, Jian Luo, Wei Liu, et al.. (2021). The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. The Journal of Immunology. 206(11). 2714–2724. 11 indexed citations
3.
Erpenbeck, Veit J., et al.. (2021). Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor. Respiratory Research. 22(1). 262–262. 8 indexed citations
4.
Müller, Meike, et al.. (2019). Fevipiprant inhibits eosinophil activation induced by multiple metabolites of prostaglandin D2. PA4391–PA4391. 2 indexed citations
5.
Hardman, Clare S., Wentao Chen, Paul Batty, et al.. (2018). Fevipiprant, a Selective Prostaglandin D-2 Receptor 2 Antagonist, Potently Inhibits Chemotaxis and Cytokine Production by Group 2 Innate Lymphoid Cells. American Journal of Respiratory and Critical Care Medicine. 197. 1 indexed citations
6.
Domingo, Christian, Óscar Palomares, David A. Sandham, Veit J. Erpenbeck, & Pablo Altman. (2018). The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation. Respiratory Research. 19(1). 189–189. 66 indexed citations
7.
Chen, Wentao, Clare S. Hardman, Paul Batty, et al.. (2018). Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s). Oxford University Research Archive (ORA) (University of Oxford). PA4401–PA4401.
8.
Shaw, Duncan, et al.. (2017). Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. Journal of Medicinal Chemistry. 60(16). 6867–6879. 3 indexed citations
9.
Sykes, David A., Darren Riddy, John Reilly, et al.. (2016). Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. Molecular Pharmacology. 89(5). 593–605. 54 indexed citations
10.
Erpenbeck, Veit J., Eva Vets, Lien Gheyle, et al.. (2015). Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. 5(4). 306–313. 22 indexed citations
11.
Beattie, David T., David Beer, Ian C. Bruce, et al.. (2012). An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol. Bioorganic & Medicinal Chemistry Letters. 22(19). 6280–6285. 24 indexed citations
12.
Reilly, John, et al.. (2011). Synthesis of useful fragments in drug discovery: 2-Amino-5-tert-butylpyridine and its oxidised analogues. Bioorganic & Medicinal Chemistry Letters. 21(14). 4281–4283.
13.
Morris, Thomas W., David A. Sandham, & Stephen Caddick. (2007). A microwave enhanced cross-metathesis approach to peptidomimetics. Organic & Biomolecular Chemistry. 5(7). 1025–1025. 13 indexed citations
14.
McCarroll, Andrew J., David A. Sandham, Alexandra K. de K. Lewis, et al.. (2003). Studies on high-temperature amination reactions of aromatic chlorides using discrete Palladium-N-Heterocyclic Carbene (NHC) complexes and in situ palladium/imidazolium salt protocols. Molecular Diversity. 7(2-4). 115–123. 19 indexed citations
15.
Sandham, David A., et al.. (2001). ChemInform Abstract: A Convergent Synthesis of the Renin Inhibitor CGP60536B.. ChemInform. 32(11). 1 indexed citations
16.
Sandham, David A., Roger Taylor, John Carey, & Alexander Fässler. (2000). A convergent synthesis of the renin inhibitor CGP60536B. Tetrahedron Letters. 41(51). 10091–10094. 37 indexed citations
17.
Gazzard, Lewis, William B. Motherwell, & David A. Sandham. (1999). Rhodium promoted isomerisation of allylic alkoxides: a new method for enolate anion formation. Journal of the Chemical Society Perkin Transactions 1. 979–994. 37 indexed citations
18.
Sandham, David A. & A. I. MEYERS. (1995). Chiral bicyclic lactams–an asymmetric synthesis of the framework of the Lycopodium alkaloid magellanine containing all six adjacent stereogenic centres. Journal of the Chemical Society Chemical Communications. 2511–2512. 19 indexed citations
19.
Edwards, Gavin L., et al.. (1991). A new route to enolate anion chemistry. Journal of the Chemical Society Chemical Communications. 1399–1399. 15 indexed citations
20.
Nicolle, L. E., et al.. (1986). An Outbreak of Group A Streptococcal Bacteremia in an Intensive Care Unit. Infection Control. 7(3). 177–180. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tai Wei Ly Breakdown of academic impact, for papers by Arthur G. Romero Breakdown of academic impact, for papers by Koichi Nishi Breakdown of academic impact, for papers by Lin Chu Breakdown of academic impact, for papers by Fujio Asanuma Breakdown of academic impact, for papers by Herman J. Crowley Breakdown of academic impact, for papers by Frederick Wong Breakdown of academic impact, for papers by Kazuaki Naito Breakdown of academic impact, for papers by Naoyuki Masuda Breakdown of academic impact, for papers by Earl F. Kimble
Rankless by CCL
2026